Presidio Ospedaliero San Giovanni Di Dio
- Address
- lock Available on a paid plan
Presidio Ospedaliero San Giovanni Di Dio
Presidio Ospedaliero San Giovanni Di Dio is a distinguished clinical research center conducting advanced Phase 3 trials across multiple therapeutic areas. The center demonstrates particular expertise in oncology and dermatology, participating in pivotal studies that evaluate novel targeted therapies and biologic treatments for complex medical conditions.
- HER2-positive metastatic colorectal cancer targeted therapy research
- Advanced dermatologic conditions including moderate to severe plaque psoriasis
- Comparative effectiveness studies of novel therapeutic agents versus standard of care
The center's research portfolio includes investigation of tucatinib combination therapy for HER2+ metastatic colorectal cancer and evaluation of JNJ-77242113 for plaque psoriasis. Their participation in multicenter, randomized, placebo-controlled trials demonstrates commitment to generating high-quality evidence through rigorous study designs with blinded independent central review assessments and active comparator controls.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Presidio Ospedaliero San Giovanni Di Dio
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK) | Bristol-Myers Squibb Services Unlimited Company | Phase I | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Deucravacitinib | 2 | Unknown | 2024-01-18 | 2026-05-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.